文献速递膀胱癌与上尿路尿路上皮癌

铂类难治性尿路上皮癌帕博利珠单抗治疗后再次挑战化疗

Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
PubMed 文献 · BJU Int · 2022-09-26

OBJECTIVES: To assess the real-world clinical benefit of re-challenging chemotherapy after pembrolizumab in patients with metastatic urothelial carcinoma (mUC), as there have been several reports suggesting that programmed cell death protein-1/programmed death-ligand 1inhibitors …

要点

  • 帕博利珠单抗进展后再次挑战化疗组中位OS 13.9个月,继续帕博利珠单抗组5.8个月(P=0.048)。
  • 再次挑战化疗的25例中20例(80%)接受含铂方案,客观缓解率为28%。
  • 以吉西他滨联合顺铂及紫杉醇(GCP)为再次挑战方案者12/25例(48%),其客观缓解率为50%。

核心结论

  • 帕博利珠单抗治疗出现疾病进展后,再次挑战含铂化疗可为转移性尿路上皮癌患者带来临床获益。

研究设计与样本

  • 从236例接受帕博利珠单抗治疗的患者中排除45例随访期间未出现疾病进展者及86例因诊断疾病进展后仅接受最佳支持治疗而停用帕博利珠单抗者,共105例纳入分析。
  • 采用逻辑回归倾向性评分模型比较疾病进展后继续帕博利珠单抗(80例)与再次挑战化疗(25例)患者的生存结局,倾向性评分匹配后识别出34例配对的匹配组。

主要发现

  • 105例患者从帕博利珠单抗治疗出现疾病进展起的中位总生存为11个月。
  • 再次挑战化疗的25例中,20例(80%)接受含铂化疗(吉西他滨联合顺铂;吉西他滨/顺铂/紫杉醇[GCP];甲氨蝶呤、长春碱、阿霉素联合顺铂;甲氨蝶呤、卡铂、长春碱联合方案MCAVI)。
  • 105例患者一线化疗的客观缓解率为30%,再次挑战化疗的25例患者客观缓解率为28%。
  • 25例中12例(48%)以GCP作为再次挑战方案,该方案的客观缓解率为50%。
  • 倾向性评分匹配后,再次挑战化疗组的总生存显著长于继续帕博利珠单抗组(中位13.9个月 vs 5.8个月,P=0.048)。

临床怎么用

  • 作者认为,帕博利珠单抗治疗出现疾病进展后再次挑战含铂化疗可为转移性尿路上皮癌患者带来临床获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the real-world clinical benefit of re-challenging chemotherapy after pembrolizumab in patients with metastatic urothelial carcinoma (mUC), as there have been several reports suggesting that programmed cell death protein-1/programmed death-ligand 1inhibitors can restore platinum sensitivity. PATIENTS AND METHODS: Of 236 patients treated with pembrolizumab, we excluded 45 patients who did not experience progressive disease (PD) for pembrolizumab during the follow-up and 86 patients who discontinued pembrolizumab by the diagnosis of PD followed by the best supportive care. A total of 105 patients were identified for a logistic regression propensity score model to compare the survival outcomes between patients treated with continuing pembrolizumab (80) and re-challenging chemotherapy (25) after the diagnosis of PD for pembrolizumab. RESULTS: A median overall survival (OS) from PD for pembrolizumab was 11 months in 105 patients. Of 25 patients treated with re-challenging chemotherapy, platinum-including chemotherapy (gemcitabine and cisplatin; gemcitabine/cisplatin/paclitaxel [GCP]; methotrexate and vinblastine and adriamycin and cisplatin; and methotrexate and carboplatin and vinblastine MCAVI) was offered in 20 patients (80%). The objective response rate (ORR) for the first-line chemotherapy in the 105 patients was 30%, with a comparable ORR in 25 patients treated with re-challenging chemotherapy of 28%. GCP as a re-challenging regimen was offered in 12 of 25 (48%) patients. The ORR for the GCP regimen was 50%. Propensity score matching was performed using putative clinical factors, from which 34 patients were identified as pair-matched groups. The OS for patients treated with re-challenging chemotherapy was significantly longer than continuing pembrolizumab (a median of 13.9 and 5.8 months, respectively: P = 0.048). CONCLUSION: Re-challenging chemotherapy including platinum agents after PD with pembrolizumab offers clinical benefits in patients with mUC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Uchimoto T, Fukushima T, Komura K, et al. Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma. BJU Int. 2022. PMID: 36098556. doi:10.1111/bju.15893

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。